GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gene One Life Science 011000.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩23.93bn

FY2016FY2025

Net income

−₩47.66bn

FY2016FY2025

Free cash flow

−₩16.55bn

FY2016FY2025

Shareholders' equity

₩40.90bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩23.93bn₩35.72bn₩40.20bn₩48.72bn₩38.70bn₩41.50bn₩41.24bn₩34.29bn₩27.17bn₩31.37bn
Research and development₩1.93bn₩3.56bn₩7.04bn₩12.15bn₩11.44bn₩8.40bn₩5.87bn₩5.66bn₩8.40bn₩3.93bn
Operating income−₩46.80bn−₩46.60bn−₩76.47bn−₩40.08bn−₩27.51bn−₩18.46bn−₩8.21bn−₩10.34bn−₩24.86bn−₩13.16bn
Net income−₩47.66bn−₩48.54bn−₩77.77bn−₩38.15bn−₩15.95bn−₩18.65bn−₩7.62bn−₩11.90bn−₩23.73bn−₩15.60bn
Diluted earnings per share-13,950.99-15,199.99-24,841.26-12,299.73-5,684.18-6,761.82-4,557.10-7,354.67-19,256.40-11,647.95

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩119.21bn₩151.33bn₩151.01bn₩222.87bn₩249.50bn₩136.57bn₩51.15bn₩49.30bn₩45.63bn₩65.66bn
Cash and short-term investments₩3.21bn₩1.75bn₩9.99bn₩45.60bn₩107.40bn₩90.52bn₩17.48bn₩22.69bn₩22.65bn₩38.32bn
Total liabilities₩78.31bn₩65.73bn₩39.52bn₩41.40bn₩44.04bn₩38.06bn₩27.09bn₩19.89bn₩9.09bn₩29.81bn
Debt₩32.96bn₩27.13bn₩17.16bn₩19.67bn₩18.40bn₩17.77bn₩14.49bn₩12.39bn₩1.46bn₩22.07bn
Shareholders' equity₩40.90bn₩85.61bn₩111.49bn₩181.47bn₩206.51bn₩98.51bn₩24.06bn₩29.41bn₩36.54bn₩35.85bn
Shares outstanding3m3m3m3m3m3m2m2m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩16.52bn−₩16.06bn−₩21.74bn−₩24.11bn−₩4.85bn−₩15.92bn−₩1.27bn−₩7.27bn−₩4.04bn−₩12.39bn
Capital spending−₩23.8m−₩3.37bn−₩5.65bn−₩45.41bn−₩82.52bn−₩16.37bn−₩3.01bn−₩3.64bn−₩412.6m−₩2.13bn
Free cash flow−₩16.55bn−₩19.42bn−₩27.40bn−₩69.52bn−₩87.37bn−₩32.29bn−₩4.28bn−₩10.91bn−₩4.45bn−₩14.52bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩2.06bn₩2.58bn₩3.54bn₩5.08bn₩6.81bn₩8.50bn₩10.51bn₩8.89bn
Operating income−₩17.93bn−₩2.22bn−₩8.76bn−₩11.66bn−₩14.81bn−₩9.07bn−₩9.86bn−₩10.04bn
Net income−₩18.95bn−₩2.38bn−₩11.95bn−₩11.47bn−₩15.41bn−₩8.84bn−₩15.65bn−₩10.60bn
Diluted earnings per share-1,091.00-137.14-3,497.05-3,356.86-4,510.35-2,586.73-4,900.17-3,320.60
Cash from operations−₩5.05bn−₩2.84bn−₩1.75bn−₩3.61bn−₩7.68bn−₩3.48bn−₩686.0m−₩3.23bn
Capital spending——−₩18.0m−₩10.0m−₩5.0m—−₩1.67bn−₩958.0m
Free cash flow——−₩1.76bn−₩3.62bn−₩7.68bn—−₩2.36bn−₩4.19bn
Total assets₩124.42bn₩131.29bn₩120.68bn₩125.54bn₩126.67bn₩144.23bn₩151.33bn₩138.23bn
Cash and short-term investments—₩6.82bn₩3.21bn₩2.71bn₩2.72bn₩3.94bn₩1.75bn₩3.63bn
Debt₩21.50bn₩31.76bn₩32.64bn₩27.52bn₩22.79bn₩26.29bn₩22.65bn₩18.93bn
Shareholders' equity₩35.69bn₩51.15bn₩45.16bn₩55.36bn₩62.49bn₩76.38bn₩85.61bn₩88.28bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-21.1%-10.4%-1.7%
Operating income5.3%20.4%29.1%
Net income7.7%20.6%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-156.6%-141.3%-111.9%-80.8%
Net margin-161.3%-142.8%-107.8%-77.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.7-0.7-0.6-2.9-14.3-10.2-1.6-1.5-0.8-2.4
Price to sales1.40.91.12.35.94.60.30.50.71.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Dec 2003.

FY2004FY2003FY2002FY2001FY2000FY1999
Paid in the year14.88422.32722.32722.32722.3275.582
  • 1.2-for-1 split · 4 Jun 2024
  • 1.2-for-1 split · 23 Feb 2024
  • 1.2-for-1 split · 24 Jan 2024
  • 1.2-for-1 split · 22 Jan 2024
  • 1.2-for-1 split · 15 Nov 2023
  • 1.2-for-1 split · 25 Oct 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.